SCHEMBL16447465

SCHEMBL16447465

COC(=O)CC[C@@H](C(=O)O)N(C=O)c1ccc(F)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 2/20 0.39
CA12 O43570 1/20 0.37
CA2 P00918 1/20 0.37
CA7 P43166 1/20 0.37
CA9 Q16790 1/20 0.37
CA14 Q9ULX7 1/20 0.37
SLC1A1 P43005 1/20 0.37
MAPT P10636 4/20 0.35
ALDH1A1 P00352 3/20 0.35
HTT P42858 1/20 0.35
POLB P06746 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
MDM2 Q00987 3/20 0.35
CYP11B1 P15538 1/20 0.34
CYP11B2 P19099 1/20 0.34
ATM Q13315 1/20 0.34
MAPK13 O15264 1/20 0.33
MAPK12 P53778 1/20 0.33
MAPK11 Q15759 1/20 0.33
MAPK14 Q16539 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17981441 0.86 KDM4E (0.40) SLC1A1MAPTALDH1A1
SCHEMBL17981361 0.86 KDM4E (0.40) SLC1A1MAPTALDH1A1
SCHEMBL17981423 0.81 QPCT (0.36) SLC1A1MAPTTSHR
SCHEMBL17981495 0.81 ALDH1A1 (0.36) SLC1A1MAPTALDH1A1SMN1; SMN2TSHR
SCHEMBL17981343 0.76 MME (0.36) FOLH1
SCHEMBL17981451 0.75 ALDH1A1 (0.39) MAPTALDH1A1MAPK13MAPK12MAPK11
SCHEMBL17981424 0.74 RAB9A (0.38) MAPTALDH1A1CYP11B1CYP11B2SMN1; SMN2
SCHEMBL6298147 0.68 ALDH1A1 (0.43) FOLH1CA12CA7CA9CA14
SCHEMBL6299671 0.68 ALDH1A1 (0.43) FOLH1CA12CA7CA9CA14
SCHEMBL639305 0.67 MAPT (0.49) CA12CA2CA7CA9CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4559902-A2 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE Imago Biosciences Inc. (US) 2025-05-28 EP disclosed
EP-3256218-B1 A KDM1A INHIBITOR AND ITS USE IN THERAPY IMAGO BIOSCIENCES INC (US) 2024-12-11 EP disclosed
US-11773068-B2 KDM1A inhibitors for the treatment of disease IMAGO BIOSCIENCES, INC. (US) 2023-10-03 US disclosed
US-11773068-B2 KDM1A inhibitors for the treatment of disease IMAGO BIOSCIENCES, INC. (US) 2023-10-03 US disclosed
US-11773068-B2 KDM1A inhibitors for the treatment of disease IMAGO BIOSCIENCES, INC. (US) 2023-10-03 US disclosed
US-11655226-B2 KDM1A inhibitors for the treatment of disease IMAGO BIOSCIENCES, INC. (US) 2023-05-23 US disclosed
US-11655226-B2 KDM1A inhibitors for the treatment of disease IMAGO BIOSCIENCES, INC. (US) 2023-05-23 US disclosed
US-11655226-B2 KDM1A inhibitors for the treatment of disease IMAGO BIOSCIENCES, INC. (US) 2023-05-23 US disclosed
US-20220073477-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. 2022-03-10 US disclosed
US-11230534-B2 KDM1A inhibitors for the treatment of disease IMAGO BIOSCIENCES, INC. (US) 2022-01-25 US disclosed
US-20160257662-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. 2016-09-08 US disclosed
US-20160257662-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. 2016-09-08 US disclosed
US-20160237043-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. 2016-08-18 US disclosed
US-20160237043-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. 2016-08-18 US disclosed
US-20160237043-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. 2016-08-18 US disclosed
WO-2016130952-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. (US) 2016-08-18 WO disclosed
WO-2016130952-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. (US) 2016-08-18 WO disclosed
EP-3030323-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE Imago Biosciences Inc. (US) 2016-06-15 EP disclosed
WO-2015021128-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES INC. (US) 2015-02-12 WO disclosed
WO-2015021128-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES INC. (US) 2015-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160257662-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1B, KDM1A, KDM2A FOLH1 3931/4885CA12 4285/4885CA2 3532/4885
US-11230534-B2 KDM1A inhibitors for the treatment of disease KDM1B, KDM1A, KDM2A FOLH1 3753/4885CA12 4225/4885CA2 3486/4885
US-20160237043-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1B, KDM1A, KDM2A FOLH1 3753/4885CA12 4225/4885CA2 3486/4885
US-20220073477-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1B, KDM1A, KDM2A FOLH1 3753/4885CA12 4225/4885CA2 3486/4885
US-11773068-B2 KDM1A inhibitors for the treatment of disease KDM1B, KDM1A, KDM2A FOLH1 3753/4885CA12 4225/4885CA2 3486/4885
US-11655226-B2 KDM1A inhibitors for the treatment of disease KDM1B, KDM1A, KDM2A FOLH1 3753/4885CA12 4225/4885CA2 3486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.